Simplify your anticoagulant testing
Learn how the INNOVANCE® Anti-Xa assay1 helps streamline lab operations with a ready-to-use assay for heparin and direct oral anticoagulant (DOAC) testing.
The INNOVANCE Anti-Xa assay1 supports improved diagnostic accuracy in heparin and DOAC testing
By combining heparin and DOAC testing into one simple and easy-to-use assay, the INNOVANCE Anti-Xa assay1 streamlines handling, reduces order complexity, and offers labs an economical testing outcome. Unlike most commercially-available solutions, this assay requires no manual preparation or waiting time.
Anticoagulant testing, simplified
- Liquid reagents require no manual preparation or reconstitution, allowing staff to concentrate on high-value tasks.
- Combined testing solution reduces handling, material, and ordering complexity for the lab.
- Single calibration curve for both types of heparin (UFH and LMWH) streamlines result interpretation and eliminates the risk of evaluation on the wrong curve.
Why your lab should perform anti-Xa testing for anticoagulants
To monitor and manage bleeding risks, labs are asked to safeguard anticoagulant therapies such as heparin or direct oral anticoagulants (DOACs) by testing patients for a growing number of agents.
Why accurate DOAC assessment is imperative
Direct oral anticoagulants such as rivaroxaban and apixaban are direct anti-Xa inhibitor drugs that have evolved over time because of their convenient dosing and short half-life. Though the medication usually does not require monitoring, DOAC testing is needed to properly manage individuals with bleeding conditions, emergency situations that require unplanned surgery, and relevant comorbidities (e.g., renal insufficiency).
Why anti-Xa is the better choice for heparin testing
Heparin is a traditional anticoagulant drug that exists in two forms—UFH and LMWH—both of which considerably accelerate the inactivation of coagulation factor Xa by antithrombin. Clinical data shows that monitoring heparin with an anti-Xa assay has several advantages over APTT testing:2-6
- A smoother dose-response curve
- More-stable heparin levels during therapy
- Fewer blood samples required
- Fewer dosage adjustments
Improved outcomes for labs of any size
The INNOVANCE Anti-Xa assay1 is available on multiple platforms and supports improved outcomes for labs
of any size.
For details on available assay applications or ordering information, download a copy of the hemostasis reagent portfolio catalog.
1
Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.
2
Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546-58.
3
Vandiver JW, Vondracek TG. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Hosp Pract. 2013;41(2):16-24.33
4
Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, Rodriquez D, Weinstein S. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2014;15(2):e72-9.
5
Adatya S, Uriel N, Yarmohammadi H, Holley CT, Feng A, Roy SS, Reding MT, John R, Eckman P, Zantek ND. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. JACC Heart Fail. 2015;3(4):314-22.
6
van Roessel S, Middeldorp S, Cheung YW, Zwinderman AH, de Pont AC. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. Neth J Med. 2014;72(6):305-10. Free access: http://www.njmonline.nl/getpdf.php?id=1463
INNOVANCE and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. Sysmex is a trademark of Sysmex Corp. All other trademarks and brands are the property of their respective owners.
Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.